Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Kevin Alexander, MD
Difelikefalin: Managing CKD-aP for Improved Quality of Life
Jörg Latus, MD
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
Ahmad Masri, MD, MS
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
Amy Mottl, MD, MPH
Prof. Christoph Wanner
New Insights in the Management of HCM: Exploring the Clinical Spectrum
August 30, 2025
Madrid
Optimizing Outcomes in Patients with oHCM: The Emerging Role of Cardiac Myosin Inhibitors
August 31, 2025
Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
Muthiah Vaduganathan, MD, MPH
Anuradha Lala-Trindade, MD
Brendon Neuen, MBBS, PhD
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
prof. Hiddo Heerspink
Jennifer B. Green, MD
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Robert J. Mentz, MD, FHFSA, FACC, FAHA
Piotr Ponikowski, MD, PhD, FESC, FHFA
Shifting Treatment Paradigm in HFmrEF/HFpEF: Steroidal and Nonsteroidal MRAs
Faiez Zannad, MD, PhD
John McMurray, MD
Remnant Cholesterol: The Missing Link in ASCVD risk
Børge G. Nordestgaard, MD, DMSc
Kausik Ray, MBChB, MD, MPhil
Targeting Mixed Hyperlipidemia with APOC3 Inhibition
Pam R. Taub, MD, FACC, FASPC
FCS: Enhancing the Diagnosis
Daniel Gaudet, MD, PhD
APOC3 Inhibition: A Novel Approach to Lowering TGs
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Jan T. Kielstein, MD, FASN, FERA
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Akshay S. Desai, MD
Loading...
We're glad to see you're enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.